12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Moxifloxacin: Phase II started

The TB Alliance began the open-label, international Phase II NC-002 trial to evaluate the combination of PA-824, moxifloxacin and pyrazinamide for 8 weeks in about 230 patients. Patients will receive 100 or 200 mg PA-824 once daily in combination with 1,500 mg pyrazinamide once daily...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >